Sign Up For Free » Here's a closer look at three discounted S&P 500 dividend stocks you can feel good about buying and ...

Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq.

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

Merck posted strong Q4 earnings, with a 7% revenue increase to $15.62 billion, beating expectations. Growth was driven by ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

A study on mice with melanoma found that aspirin lowered TXA2 levels, which freed up T cells and allowed them to fight cancer more effectively. However, the lead scientist stressed that long-term ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Tesla has its second straight difficult month in Germany, as data released Wednesday showed that vehicle registrations fell 76% in February in Europe's largest economy. The company has asked the U.S.

Foot Locker's fiscal 2026 earnings guidance sharply misses analysts' expectations. The retailer reported fourth-quarter earnings and sales that narrowly beat estimates. Before joining the discount ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...